The SIR-POBA Shunt Trial

NCT ID: NCT06056206

Last Updated: 2025-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-20

Study Completion Date

2027-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare plain old balloon angioplasty with sirolimus-coated balloon angioplasty in patients with an arteriovenous shunt stenosis. The main question we aim to answer is, how patency is affected by each of the randomised treatment modality.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial will be conducted at our Division of Vascular Surgery and Endovascular Surgery at the University Hospital of Salzburg. Patients will be randomized into one of the two treatment options (plain old ballon angioplasty versus sirolimus coated balloon angioplasty). The recruitment phase is calculated for two years with a planned follow-up of 2 years. Follow-up data will be collected to answer the endpoints and will include all available follow-ups to monitor the shunt up to 2 years after the procedure. Typically, follow-up visits will be conducted at 6 weeks, 3 months, 6 months, 12 months, and 24 months after the procedure.

The shunts are checked for functionality as part of the dialysis required three times a week and presented to our department beforehand in need. This saves chronically ill patients the additional waiting time in hospital outpatient departments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arteriovenous Fistula Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Plain Balloon Angioplasty

Plain Balloon Angioplasty will be used to treat lesions.

Group Type ACTIVE_COMPARATOR

Balloon Angioplasty

Intervention Type RADIATION

Revascularisation procedures will be performed according to randomised list.

Sirolimus-coated Balloon Angioplasty

Sirolimus-coated Balloon Angioplasty will be used to treat lesions after preparing vessel with plain balloon angioplasty.

Group Type ACTIVE_COMPARATOR

Balloon Angioplasty

Intervention Type RADIATION

Revascularisation procedures will be performed according to randomised list.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Balloon Angioplasty

Revascularisation procedures will be performed according to randomised list.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Endovascular Revascularization

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age at least 18 years
* Informed consent with signature
* Maturated shunt, defined as already in use for two weeks
* Shunt stenosis in need of intervention

Exclusion Criteria

* Pregnant or breastfeeding women
* Active infection or sepsis
* Incapacitated patients
* Lesions in the affected stenosis already pretreated by stenting in the same area shunt.
* Patients currently participating in another study
* Central venous stenosis worthy of treatment
* intolerance to sirolimus
* coagulopathy
* radiotherapy
* patients on immunosuppressive therapy
* use of potent CYP3A4 and/or P-gp inhibitors (such as ketoconazole, Voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong CYP3A4 and/or P-gp inducers (such as rifampin or rifabutin).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedAlliance Swiss Medical Technology

UNKNOWN

Sponsor Role collaborator

Paracelsus Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Manuela Pilz

Senior physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephanie Rassam, MD

Role: STUDY_CHAIR

Resident Physician

Manuela Pilz, MD PD FEBVS

Role: PRINCIPAL_INVESTIGATOR

Senior Physician

Klaus Linni, MD PD FEBVS

Role: STUDY_DIRECTOR

Head of Division of Vascular and Endovascular Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Salzburg, Paracelsus Medical University

Salzburg, Salzburg, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1037/2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Zilver® PTX™ Global Registry
NCT01094678 COMPLETED NA
Stellarex Vascular E-Registry
NCT02769273 COMPLETED
SELUTION4SFA Trial
NCT05132361 ACTIVE_NOT_RECRUITING NA